Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Weishang (Shanghai) Bio-Pharmaceutical Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner and 1 distinct art unit, concentrating the company's current legal focus. This singular focus indicates that the company's active patent prosecution is limited to one specific technical area.
SHIM, DAVID M. is the busiest examiner, responsible for the 1 pending office action. This single examiner's review will determine the outcome for the company's only currently active office action. Without other pending cases, the company cannot leverage multiple examiner relationships to advance its intellectual property goals.
Practitioners should note that the 1 pending office action is the only matter currently requiring attention from the company. Because this action is assigned to 1 distinct art unit, the prosecution must strictly adhere to the technical and procedural norms of that specific group. The company's immediate path to allowance is entirely dependent on the assessment provided by SHIM, DAVID M.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIM, DAVID M. | 1 | 58.8% | +58.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292307 | A 6-substituted Chiral Pure Difluoropiperidine Quinazoline Derivative And Its Preparation Method | SHIM, DAVID M. | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18292307 | A 6-substituted Chiral Pure Difluoropiperidine Quinazoline Derivative And Its Preparation Method | SHIM, DAVID M. | 1626 | §112 | Non-Final OA | — | Pending | Jan 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWeishang (Shanghai) Bio-Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David M. Shim has the most, with 1 of Weishang (Shanghai) Bio-Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
